The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $20.95 in the prior trading day, Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) closed at $20.75, down -0.95%. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 1.4 million shares were traded. CPRX stock price reached its highest trading level at $21.25 during the session, while it also had its lowest trading level at $20.62.
Ratios:
Our goal is to gain a better understanding of CPRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.46. For the most recent quarter (mrq), Quick Ratio is recorded 5.96 and its Current Ratio is at 6.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 10 ’25 when Sundaram Preethi sold 2,324 shares for $26.41 per share. The transaction valued at 61,377 led to the insider holds 42,681 shares of the business.
Sundaram Preethi sold 1,600 shares of CPRX for $42,272 on Jun 11 ’25. The Chief Strategy Officer now owns 41,081 shares after completing the transaction at $26.42 per share. On Jun 11 ’25, another insider, Sundaram Preethi, who serves as the Officer of the company, bought 1,600 shares for $26.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2530981376 and an Enterprise Value of 2069295744. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.24, and their Forward P/E ratio for the next fiscal year is 11.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.73 while its Price-to-Book (P/B) ratio in mrq is 3.19. Its current Enterprise Value per Revenue stands at 3.87 whereas that against EBITDA is 7.688.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.71, which has changed by 0.34217334 over the last 52 weeks, in comparison to a change of 0.10500872 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is -12.28%, while the 200-Day Moving Average is calculated to be -7.33%.
Shares Statistics:
The stock has traded on average 1.20M shares per day over the past 3-months and 1314870 shares per day over the last 10 days, according to various share statistics. A total of 121.96M shares are outstanding, with a floating share count of 111.11M. Insiders hold about 8.91% of the company’s shares, while institutions hold 79.38% stake in the company. Shares short for CPRX as of 1749772800 were 7728086 with a Short Ratio of 6.46, compared to 1747267200 on 7425676. Therefore, it implies a Short% of Shares Outstanding of 7728086 and a Short% of Float of 8.1.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
